Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
What pen should be used for Lyumjev® (insulin lispro) cartridges?
The HumaPen® SAVVIO™ is the Lilly reusable pen available for use with Lyumjev cartridges. Patients should not use other reusable pens, as Lilly has not established dosing accuracy with other pens.
What is the HumaPen SAVVIO?
HumaPen SAVVIO is designed for ease of use.1
- It injects from 1 to 60 units of insulin in each injection.
- The patient can dial the dose in steps of one (1) unit at a time.
- HumaPen SAVVIO is for use only with Lilly 3 ml insulin cartridges.
- Other brands of insulin cartridges should not be used in this pen.
- The colour of the pen is not intended to indicate insulin type.
HumaPen SAVVIO is suitable for use with BD (Becton, Dickinson and Company) Pen needles.1
1HumaPen® Savvio [instructions for use]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 09 December 2022